Knight Supports Operation Antibe
MONTREAL, QUEBEC–(Marketwired – Nov 16, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has purchased $500,000 of senior secured convertible debentures (the “Debentures”) offered by Antibe Therapeutics Inc. (“Antibe”) (TSX VENTURE:ATE)(OTCQX:ATBPF) as part of a $2.6 million private placement. The proceeds will be used to further […]
Knight Reports Third Quarter Financial 2015 Results
MONTREAL, CANADA–(Marketwired – Nov 11, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported its third quarter ended September 30, 2015 financial results. Third Quarter 2015 Highlights Product Development Entered into an exclusive Canadian distribution agreement with Alimera Sciences, Inc. for ILUVIEN®, a sustained release intravitreal […]
The Knight Medison Relationship Already Paying Dividends
MONTREAL, QUEBEC–(Marketwired – Nov 2, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that a dividend to Knight in the amount of NIS 5.66 million [C$1.9 million] has been approved by the Board of Directors of Medison (1995) Ltd. (“Medison”) The dividend relates to Knight’s 28.3% equity interest […]
Knight Profounda U.S. Partner for Impavido
MONTREAL, QUEBEC–(Marketwired – Sep 28, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries, (“Knight”) announced today that it has entered into an exclusive distribution agreement with Profounda Inc. (“Profounda”) to commercialize Impavido®(miltefosine), an oral treatment for visceral, mucosal and cutaneous leishmaniasis, in the United States. Knight previously licensed the ex-U.S. global […]
Knight Takes its Dose of Medison
MONTREAL, CANADA–(Marketwired – Sep 9, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today its previously announced transaction with Medison Biotech (1995) Ltd. (“Medison”), Israel’s leading independent specialty pharmaceutical company, has closed. To solidify the strategic collaboration between the companies, Knight has acquired a 28.3% equity interest in Medison […]
GUD Medison Taken at Knight
MONTREAL, CANADA and PETAH TIKVA, ISRAEL–(Marketwired – Aug 31, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, and Medison Biotech (1995) Ltd. (“Medison”), Israel’s leading independent specialty pharmaceutical company, announced today a strategic collaboration in which the companies will join forces in their respective missions to bring innovative treatments to […]
NEMO Ascends to New High Water Mark for Knight
MONTREAL, CANADA–(Marketwired – Aug 24, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, announced today that it has received a further distribution of US$1.5 million related to its investment in Sectoral Asset Management Inc.’s New Emerging Medical Opportunities Funds II, Ltd. (“NEMO II”) following the US$13.6 million […]
Knight Reports Second Quarter 2015 Results
MONTREAL, QUEBEC–(Marketwired – Aug 12, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported its second quarter ended June 30, 2015 financial results. Second Quarter 2015 Highlights On April 2, 2015, Knight entered into an agreement with HarbourVest Partners LLC, whereby the Company committed to invest […]
Knight and LFB S.A. Announce Filing of New Drug Submission for ATryn(R)
MONTREAL, CANADA and LES ULIS, FRANCE–(Marketwired – Aug 6, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, and LFB S.A., a biopharmaceutical Group focused on innovative therapeutics for serious and rare diseases, today announced that Knight’s New Drug Submission (NDS) has been accepted for review by Health […]
Knight Sparks Ember Partnership
MONTREAL, CANADA and NEW YORK, NEW YORK–(Marketwired – Aug 5, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company and Ember Therapeutics, Inc. (“Ember”), a privately held, New York-based biotechnology company developing targeted therapies for osteoarthritis, kidney fibrosis and other indications using Bone Morphogenetic Protein-7 (“BMP-7”), announced today that Knight has […]
